Contrasting Amylyx Pharmaceuticals (NASDAQ:AMLX) & Corbus Pharmaceuticals (NASDAQ:CRBP)

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, profitability and institutional ownership.

Analyst Recommendations

This is a summary of recent ratings and target prices for Amylyx Pharmaceuticals and Corbus Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1	2	9	1	2.77
Corbus Pharmaceuticals	2	0	8	1	2.73

Amylyx Pharmaceuticals currently has a consensus target price of $23.00, suggesting a potential upside of 65.11%. Corbus Pharmaceuticals has a consensus target price of $42.33, suggesting a potential upside of 267.80%. Given Corbus Pharmaceuticals’ higher possible upside, analysts plainly believe Corbus Pharmaceuticals is more favorable than Amylyx Pharmaceuticals.

Risk and Volatility

Amylyx Pharmaceuticals has a beta of -0.11, meaning that its stock price is 111% less volatile than the S&P 500. Comparatively, Corbus Pharmaceuticals has a beta of 2.68, meaning that its stock price is 168% more volatile than the S&P 500.

Earnings & Valuation

This table compares Amylyx Pharmaceuticals and Corbus Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	N/A	N/A	-$144.74 million	($1.50)	-9.29
Corbus Pharmaceuticals	N/A	N/A	-$78.54 million	($5.82)	-1.98

Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Amylyx Pharmaceuticals and Corbus Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%
Corbus Pharmaceuticals	N/A	-70.89%	-61.78%

Institutional and Insider Ownership

95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are held by institutional investors. 12.3% of Amylyx Pharmaceuticals shares are held by company insiders. Comparatively, 3.5% of Corbus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Amylyx Pharmaceuticals beats Corbus Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.